Accessibility Menu
Innoviva logo

Innoviva(NASDAQ) INVA

Market Cap$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2004)+56%
5 Year+50%
1 Year+15%
1 Month-7%
$20.85
-1.74%
-0.37Today
Innoviva last closing stock price
MetricPriceDate
Last closeUSD 21.222026-07-30
Innoviva stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+0.09%USD 21.202026-07-23
1 month-6.56%USD 22.712026-06-30
3 month-8.18%USD 23.112026-05-01
Year to date+6.15%USD 19.992025-12-31
1 year+15.14%USD 18.432025-07-30
3 year+56.61%USD 13.552023-07-31
5 year+49.65%USD 14.182021-07-30
Since inception+56.23%USD 13.582004-10-05

Innoviva Financials at a Glance

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$424.12M

Net Income (TTM)

$504.34M

EPS (TTM)

$6.01

P/E Ratio

3.53

Dividend

$0.00

Beta (Volatility)

0.38 (Low)

Price

$20.85

Volume

23,344.092

Open

$21.07

Previous Close

$21.22

Daily Range

$20.96 - $21.08

52-Week Range

$16.52 - $25.15

Estimated Earnings Date

Aug 5, 2026

INVA News

BuyAlert-Green.png

Innoviva Stock Is Up Just 10% This Past Year. Here's Why a Fund Bought $2.5 Million More

Jonathan PoncianoMay 29, 2026
Foolcom-Featured.png

Innoviva (INVA) Q2 Sales Jump 64%

Motley Fool Markets TeamAug 6, 2025
GettyImages-943401146

3 Small-Cap Stocks With Big-Cap Potential

Alex CarchidiSep 25, 2020
GettyImages-1064259834

2 Best Biotech Stocks to Buy in August

Alex CarchidiAug 9, 2020
people working in a lab

2 Incredibly Cheap Biotech Stocks

David Jagielski, CPADec 23, 2019
Microscope (2)

3 Top Biotech Stocks to Buy in April

George Budwell, PhDApr 8, 2019
Curious Man Reading Financial Newspaper Getty

3 Under-the-Radar Value Stocks to Buy in 2019

Sean WilliamsJan 1, 2019
Stethoscope Over Money Healthcare Costs Obamacare Getty

13 of the Cheapest Healthcare Stocks

Sean WilliamsAug 14, 2018
Page 1

INVA: Motley Fool Moneyball Superscore

67

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Innoviva

Innoviva manages medical royalties and sells hospital medicines. It helps doctors treat lung diseases and serious infections. The company collects fees from partners and develops drugs.

Royalties and Rare Drugs

  • Respiratory Royalties: Portfolio of medicines for asthma and chronic lung diseases; partnered with GSK for global distribution.
  • Critical Care: Direct hospital sales of Giapreza to treat patients in shock.
  • Infectious Disease: Antibiotics like Xacduro and Xerava used for severe pneumonia and abdominal infections.
  • Sexual Health: Single-dose oral treatment for gonorrhea; approved by the FDA in December 2025.

Growing the Business

  • Acquired Entasis Therapeutics in 2022 to add infectious disease expertise.
  • Purchased La Jolla Pharmaceutical in 2022 to expand hospital product offerings.
  • Licensed U.S. rights for Zevtera from Basilea Pharmaceutica Ltd in December 2024.
  • Launched Zevtera commercially in the United States during the third quarter of 2025.

What Makes Innoviva Stand Out

Innoviva combines a steady royalty stream with an active drug sales platform. The company focuses on high-need medical areas like antibiotic-resistant bacteria.

The Latest Numbers

  • Revenue reached $118 million in Q4 2025, up 28.6% year-over-year.
  • Net income hit $164.2 million in Q4 2025, up 707.4% from Q4 2024.
  • Free cash flow was $53.4 million in Q4 2025, down 3.4% year-over-year.
  • Market capitalization grew to $1.5 billion by Q4 2025, a 37.4% increase.

Bottom Line

Innoviva has transitioned from a royalty manager into a diversified drug developer. Its mix of steady royalties and new hospital products supports its operational evolution.

AI Generated • Apr 29, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

159

CEO

Pavel Raifeld, CFA, MBA

Website

www.inva.com

Headquarters

Burlingame, CA 94010, US

INVA Financials

Key Financial Metrics (TTM)

Gross Margin

76.20%

Operating Margin

14.85%

Net Income Margin

118.91%

Return on Equity

47.59%

Return on Capital

11.36%

Return on Assets

27.46%

Earnings Yield

28.33%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

73.81M

Volume

23.34K

Avg. Volume

837.30K

Financials (TTM)

Gross Profit

$323.16M

Operating Income

$62.97M

EBITDA

$639.93M

Operating Cash Flow

$183.60M

Capital Expenditure

-$2.74M

Free Cash Flow

$180.85M

Cash & ST Invst.

$611.93M

Total Debt

$331.42M

Innoviva Performance Analysis

Innoviva annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 5,508,000-98.6%
20232023-12-31USD 324,263,0005787.1%
20242024-12-31USD 372,511,00014.9%
20252025-12-31USD 425,128,00014.1%
Innoviva sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3013.1%
Q32025-09-307.5%
Q42025-12-319.5%
Q12026-03-31-17.0%
Innoviva annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -1.08N/A
20232023-12-31USD 2.20N/A
20242024-12-31USD 0.36-83.6%
20252025-12-31USD 3.30811.7%
Innoviva sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30204.1%
Q32025-09-3040.3%
Q42025-12-3179.6%
Q12026-03-3114.4%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

$97.99M

+10.6%

Gross Profit

$75.83M

-5.0%

Gross Margin

77.39%

N/A

Market Cap

$1.57BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$9.85M

N/A

Employees

159

N/A

Net Income

$186.60M

+500.6%

EBITDA

$239.17M

+972.8%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

$611.93M

+36.9%

Total Debt

$331.42M

-26.6%

Accounts Receivable

$92.63M

+18.9%

Inventory

$38.84M

-6.4%

Long Term Debt

$326.08M

+26.5%

Short Term Debt

$5.34M

-97.2%

Return on Assets

27.46%

N/A

Return on Invested Capital

3.50%

N/A

Free Cash Flow

$34.79M

-28.4%

Operating Cash Flow

$35.28M

-27.4%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SNDXSyndax Pharmaceuticals, Inc.
$18.78-3.59%
NKTRNektar Therapeutics
$70.40-1.47%
INBXInhibrx Biosciences Inc.
$81.63-3.66%
IMTXImmatics N.V.
$8.85-3.80%

Trending Stocks

Symbol / CompanyPricePrice Chg
AAPLApple
$303.23-0.09%
AMZNAmazon
$265.77+0.13%
MUUDirexion Shares ETF Trust - Direxion Daily Mu Bull 2x Shares
$27.87+0.03%
INTCIntel
$94.57+0.04%

Questions About INVA

What is the current price of Innoviva?

Innoviva is trading at $20.98 per share.

What is the 52-week range for Innoviva?

Over the past 52 weeks, Innoviva has traded between $16.52 and $25.15.

How much debt does Innoviva have?

As of the most recent reporting period, Innoviva reported total debt of $331.42M.

How much cash does Innoviva have on hand?

Innoviva reported $603.09M in cash and cash equivalents in its most recent financial results.

What is Innoviva’s dividend yield?

Innoviva does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services